All the news articles and press releases in one place.

Date / Time Source Company Sector Market Cap Announcement
01Dec21 07:00 RNS ANGLE plc Health £320.9m Angle PLC - Parsortix in RNA analysis of CTCs as tool in NSCLC
26Nov21 17:33 RNS ANGLE plc Health £320.9m Angle PLC - Issue of Equity
17Nov21 10:32 RNS ANGLE plc Health £320.9m Angle PLC - Issue of Equity
15Nov21 07:00 RNS ANGLE plc Health £320.9m Angle PLC - Appointment of Chief Medical Officer
15Nov21 07:00 RNS ANGLE plc Health £320.9m Angle PLC - Issue of LTIP Options and Share Options
12Nov21 17:51 RNS ANGLE plc Health £320.9m Angle PLC - Issue of Equity
12Nov21 07:00 RNS ANGLE plc Health £320.9m Angle PLC - Participation at Jefferies healthcare conference
11Nov21 07:00 RNS ANGLE plc Health £320.9m Angle PLC - Parsortix system showcased at NCRI Festival
10Nov21 17:40 RNS ANGLE plc Health £320.9m Angle PLC - Issue of Equity
02Nov21 07:00 RNS ANGLE plc Health £320.9m Angle PLC - Change of Adviser
21Oct21 17:25 RNS ANGLE plc Health £320.9m Angle PLC - Issue of Equity
15Oct21 17:45 RNS ANGLE plc Health £320.9m Angle PLC - Issue of Equity
30Sep21 16:02 RNS ANGLE plc Health £320.9m Angle PLC - Issue of Equity
30Sep21 07:00 RNS ANGLE plc Health £320.9m Angle PLC - Interim Results
27Sep21 07:00 RNS ANGLE plc Health £320.9m Angle PLC - Parsortix demonstrates ability to isolate CTCs
22Sep21 07:00 RNS ANGLE plc Health £320.9m Angle PLC - Study shows use of Parsortix to assess PD-L1
20Sep21 07:00 RNS ANGLE plc Health £320.9m Angle PLC - Parsortix enables gene expression analysis in mPCa
07Sep21 07:00 RNS ANGLE plc Health £320.9m Angle PLC - Notice of Interim Results and Webcast
24Aug21 07:00 RNS ANGLE plc Health £320.9m Angle PLC - Director/PDMR Shareholding
09Aug21 07:00 RNS ANGLE plc Health £320.9m Angle PLC - Study highlights superior performance of Parsortix
06Aug21 13:17 RNS ANGLE plc Health £320.9m Angle PLC - Issue of Equity
03Aug21 15:13 RNS ANGLE plc Health £320.9m Angle PLC - Issue of Equity
28Jul21 07:00 RNS ANGLE plc Health £320.9m Angle PLC - Contract secured for bespoke assay development
09Jul21 07:00 RNS ANGLE plc Health £320.9m Angle PLC - Harvesting CTCs from brain metastasis patients
07Jul21 18:34 RNS ANGLE plc Health £320.9m Angle PLC - Director/PDMR Shareholding
02Jul21 10:45 RNS ANGLE plc Health £320.9m Angle PLC - Issue of Equity
30Jun21 15:44 RNS ANGLE plc Health £320.9m Angle PLC - Result of AGM
25Jun21 07:00 RNS ANGLE plc Health £320.9m Angle PLC - Result of Accelerated Bookbuild
24Jun21 18:28 RNS ANGLE plc Health £320.9m Angle PLC - Accelerated bookbuild to raise up to £20m
18Jun21 11:42 RNS ANGLE plc Health £320.9m Angle PLC - Annual General Meeting update
18Jun21 07:00 RNS ANGLE plc Health £320.9m Angle PLC - ctDNA and CTCs have differences in EGFR mutations
04Jun21 07:00 RNS ANGLE plc Health £320.9m Angle PLC - Update on submission for FDA clearance
01Jun21 07:00 RNS ANGLE plc Health £320.9m Angle PLC - Potential to prevent breast cancer relapse
20May21 07:00 RNS ANGLE plc Health £320.9m Angle PLC - Parsortix demonstrates oesophageal cancer utility
19May21 16:37 RNS ANGLE plc Health £320.9m Angle PLC - Exercise of options and total voting rights
11May21 07:00 RNS-R ANGLE plc Health £320.9m Parsortix study uncovers targets in TNBC patients
30Apr21 11:22 RNS ANGLE plc Health £320.9m Exercise of options and total voting rights
29Apr21 07:00 RNS ANGLE plc Health £320.9m Preliminary Results
26Apr21 07:00 RNS ANGLE plc Health £320.9m Ovarian cancer study patient enrolment completed
16Apr21 07:00 RNS ANGLE plc Health £320.9m First large-scale pharma services contract secured
15Apr21 16:10 RNS ANGLE plc Health £320.9m Notice of Preliminary Results and Webcast
12Apr21 07:00 RNS-R ANGLE plc Health £320.9m ANGLE's Parsortix system showcased at AACR 2021
30Mar21 07:00 RNS ANGLE plc Health £320.9m Global launch of clinical services laboratories
04Mar21 07:00 RNS ANGLE plc Health £320.9m Update on submission for FDA clearance
18Feb21 07:00 RNS ANGLE plc Health £320.9m Parsortix-harvested CTCs uncover novel biomarker
08Feb21 07:00 RNS ANGLE plc Health £320.9m Parsortix: Dynamic assessment of patient response
26Jan21 13:00 RNS ANGLE plc Health £320.9m Holding(s) in Company
20Jan21 07:00 RNS ANGLE plc Health £320.9m Research confirms high performance of Parsortix
12Jan21 07:00 RNS-R ANGLE plc Health £320.9m Change of Auditor
05Jan21 07:00 RNS ANGLE plc Health £320.9m Issue of Equity
09Dec20 07:00 RNS-R ANGLE plc Health £320.9m Parsortix can capture single cancer cell in sample
20Nov20 16:18 RNS ANGLE plc Various Various Holding(s) in Company
18Nov20 16:51 RNS ANGLE plc Health £320.9m Holding(s) in Company
13Nov20 10:46 RNS ANGLE plc Health £320.9m Result of General Meeting
03Nov20 14:54 RNS ANGLE plc Health £320.9m Director/PDMR Shareholding
29Oct20 07:00 RNS ANGLE plc Health £320.9m Interim Results
27Oct20 18:28 RNS ANGLE plc Health £320.9m Result of Placing & Notice of General Meeting
27Oct20 07:00 RNS ANGLE plc Health £320.9m Accelerated bookbuild to raise up to £20m
20Oct20 07:00 RNS-R ANGLE plc Health £320.9m Submission accepted by FDA for substantive review
28Sep20 07:00 RNS ANGLE plc Health £320.9m Issue of LTIP Options and Share Options
28Sep20 07:00 RNS ANGLE plc Health £320.9m ANGLE announces completion of FDA submission
23Sep20 07:00 RNS ANGLE plc Health £320.9m Potential treatment strategy to limit metastasis
11Sep20 15:35 RNS Legal & General Group Plc Various Various Holding(s) in Company
11Sep20 15:30 RNS ANGLE plc Health £320.9m Holding(s) in Company
02Sep20 13:49 RNS ANGLE plc Health £320.9m Notification of Interim Results and Webcast
02Sep20 10:00 RNS ANGLE plc Various Various Holding(s) in Company
27Aug20 15:13 RNS ANGLE plc Health £320.9m Result of 2020 Annual General Meeting
18Aug20 09:30 RNS ANGLE plc Various Various Holding(s) in Company
14Aug20 07:00 RNS ANGLE plc Health £320.9m Parsortix use to assess response to immunotherapy
06Aug20 12:20 RNS ANGLE plc Various Various Holding(s) in Company
05Aug20 07:00 RNS ANGLE plc Health £320.9m Notice of AGM and Posting of Annual Report
20Jul20 07:00 RNS ANGLE plc Health £320.9m Study: Parsortix use in metastatic breast cancer
08Jul20 17:35 RNS ANGLE plc Various Various Holding(s) in Company
08Jul20 17:30 RNS ANGLE plc Various Various Holding(s) in Company
08Jul20 17:30 RNS ANGLE plc Health £320.9m Holding(s) in Company
25Jun20 07:00 RNS ANGLE plc Health £320.9m Preliminary Results
22Jun20 07:00 RNS ANGLE plc Health £320.9m Blood donations recommenced for FDA studies
29May20 07:00 RNS ANGLE plc Health £320.9m Notice of Results
12May20 07:00 RNS-R ANGLE plc Health £320.9m CTC potential as biomarker in MET inhibitor trials
04May20 07:00 RNS-R ANGLE plc Health £320.9m Leading cancer centre publishes Parsortix workflow
28Apr20 07:00 RNS ANGLE plc Health £320.9m Business Update
17Apr20 07:00 RNS ANGLE plc Health £320.9m Parsortix performance in head and neck cancer
31Mar20 07:00 RNS ANGLE plc Health £320.9m COVID-19 BUSINESS IMPACT UPDATE
03Mar20 07:00 RNS ANGLE plc Health £320.9m Assessing risk of brain metastasis in lung cancer
27Feb20 07:00 RNS-R ANGLE plc Health £320.9m Parsortix outperforms other CTC systems in RCC
25Feb20 07:00 RNS-R ANGLE plc Health £320.9m ANGLE announce Tri-Con presentation with BioView
17Feb20 07:00 RNS ANGLE plc Health £320.9m Data demonstrates key advantages of Parsortix
11Feb20 07:00 RNS-R ANGLE plc Health £320.9m Study demonstrates Parsortix potential in melanoma
03Feb20 09:10 RNS ANGLE plc Health £320.9m Issue of Equity
30Jan20 07:00 RNS ANGLE plc Health £320.9m Interim Results
30Jan20 07:00 RNS ANGLE plc Health £320.9m Change of accounting reference date
22Jan20 07:00 RNS ANGLE plc Health £320.9m Successful face-to-face meeting with FDA
08Jan20 12:33 RNS ANGLE plc Health £320.9m Notice of Results
23Dec19 09:55 RNS ANGLE plc Health £320.9m Issue of Equity
07Nov19 07:00 RNS-R ANGLE plc Health £320.9m Cancer centre shows Parsortix use in melanoma
30Oct19 14:44 RNS ANGLE plc Health £320.9m Result of AGM
30Oct19 07:00 RNS ANGLE plc Health £320.9m Q-submission to FDA containing headline data
08Oct19 07:00 RNS ANGLE plc Health £320.9m Notice of AGM
04Oct19 17:54 RNS ANGLE plc Health £320.9m Holding(s) in Company
04Oct19 07:00 RNS-R ANGLE plc Health £320.9m European patent granted for megakaryocyte analysis
Date / Time Source Company % Chg
01Dec21 07:00 RNS ANGLE plc 5.40%
Angle PLC - Parsortix in RNA analysis of CTCs as tool in NSCLC
26Nov21 17:33 RNS ANGLE plc 5.40%
Angle PLC - Issue of Equity
17Nov21 10:32 RNS ANGLE plc 5.40%
Angle PLC - Issue of Equity
15Nov21 07:00 RNS ANGLE plc 5.40%
Angle PLC - Appointment of Chief Medical Officer
15Nov21 07:00 RNS ANGLE plc 5.40%
Angle PLC - Issue of LTIP Options and Share Options
12Nov21 17:51 RNS ANGLE plc 5.40%
Angle PLC - Issue of Equity
12Nov21 07:00 RNS ANGLE plc 5.40%
Angle PLC - Participation at Jefferies healthcare conference
11Nov21 07:00 RNS ANGLE plc 5.40%
Angle PLC - Parsortix system showcased at NCRI Festival
10Nov21 17:40 RNS ANGLE plc 5.40%
Angle PLC - Issue of Equity
02Nov21 07:00 RNS ANGLE plc 5.40%
Angle PLC - Change of Adviser
21Oct21 17:25 RNS ANGLE plc 5.40%
Angle PLC - Issue of Equity
15Oct21 17:45 RNS ANGLE plc 5.40%
Angle PLC - Issue of Equity
30Sep21 16:02 RNS ANGLE plc 5.40%
Angle PLC - Issue of Equity
30Sep21 07:00 RNS ANGLE plc 5.40%
Angle PLC - Interim Results
27Sep21 07:00 RNS ANGLE plc 5.40%
Angle PLC - Parsortix demonstrates ability to isolate CTCs
22Sep21 07:00 RNS ANGLE plc 5.40%
Angle PLC - Study shows use of Parsortix to assess PD-L1
20Sep21 07:00 RNS ANGLE plc 5.40%
Angle PLC - Parsortix enables gene expression analysis in mPCa
07Sep21 07:00 RNS ANGLE plc 5.40%
Angle PLC - Notice of Interim Results and Webcast
24Aug21 07:00 RNS ANGLE plc 5.40%
Angle PLC - Director/PDMR Shareholding
09Aug21 07:00 RNS ANGLE plc 5.40%
Angle PLC - Study highlights superior performance of Parsortix
06Aug21 13:17 RNS ANGLE plc 5.40%
Angle PLC - Issue of Equity
03Aug21 15:13 RNS ANGLE plc 5.40%
Angle PLC - Issue of Equity
28Jul21 07:00 RNS ANGLE plc 5.40%
Angle PLC - Contract secured for bespoke assay development
09Jul21 07:00 RNS ANGLE plc 5.40%
Angle PLC - Harvesting CTCs from brain metastasis patients
07Jul21 18:34 RNS ANGLE plc 5.40%
Angle PLC - Director/PDMR Shareholding
02Jul21 10:45 RNS ANGLE plc 5.40%
Angle PLC - Issue of Equity
30Jun21 15:44 RNS ANGLE plc 5.40%
Angle PLC - Result of AGM
25Jun21 07:00 RNS ANGLE plc 5.40%
Angle PLC - Result of Accelerated Bookbuild
24Jun21 18:28 RNS ANGLE plc 5.40%
Angle PLC - Accelerated bookbuild to raise up to £20m
18Jun21 11:42 RNS ANGLE plc 5.40%
Angle PLC - Annual General Meeting update
18Jun21 07:00 RNS ANGLE plc 5.40%
Angle PLC - ctDNA and CTCs have differences in EGFR mutations
04Jun21 07:00 RNS ANGLE plc 5.40%
Angle PLC - Update on submission for FDA clearance
01Jun21 07:00 RNS ANGLE plc 5.40%
Angle PLC - Potential to prevent breast cancer relapse
20May21 07:00 RNS ANGLE plc 5.40%
Angle PLC - Parsortix demonstrates oesophageal cancer utility
19May21 16:37 RNS ANGLE plc 5.40%
Angle PLC - Exercise of options and total voting rights
11May21 07:00 RNS-R ANGLE plc 5.40%
Parsortix study uncovers targets in TNBC patients
30Apr21 11:22 RNS ANGLE plc 5.40%
Exercise of options and total voting rights
29Apr21 07:00 RNS ANGLE plc 5.40%
Preliminary Results
26Apr21 07:00 RNS ANGLE plc 5.40%
Ovarian cancer study patient enrolment completed
16Apr21 07:00 RNS ANGLE plc 5.40%
First large-scale pharma services contract secured
15Apr21 16:10 RNS ANGLE plc 5.40%
Notice of Preliminary Results and Webcast
12Apr21 07:00 RNS-R ANGLE plc 5.40%
ANGLE's Parsortix system showcased at AACR 2021
30Mar21 07:00 RNS ANGLE plc 5.40%
Global launch of clinical services laboratories
04Mar21 07:00 RNS ANGLE plc 5.40%
Update on submission for FDA clearance
18Feb21 07:00 RNS ANGLE plc 5.40%
Parsortix-harvested CTCs uncover novel biomarker
08Feb21 07:00 RNS ANGLE plc 5.40%
Parsortix: Dynamic assessment of patient response
26Jan21 13:00 RNS ANGLE plc 5.40%
Holding(s) in Company
20Jan21 07:00 RNS ANGLE plc 5.40%
Research confirms high performance of Parsortix
12Jan21 07:00 RNS-R ANGLE plc 5.40%
Change of Auditor
05Jan21 07:00 RNS ANGLE plc 5.40%
Issue of Equity
09Dec20 07:00 RNS-R ANGLE plc 5.40%
Parsortix can capture single cancer cell in sample
20Nov20 16:18 RNS ANGLE plc 5.40%
Holding(s) in Company
18Nov20 16:51 RNS ANGLE plc 5.40%
Holding(s) in Company
13Nov20 10:46 RNS ANGLE plc 5.40%
Result of General Meeting
03Nov20 14:54 RNS ANGLE plc 5.40%
Director/PDMR Shareholding
29Oct20 07:00 RNS ANGLE plc 5.40%
Interim Results
27Oct20 18:28 RNS ANGLE plc 5.40%
Result of Placing & Notice of General Meeting
27Oct20 07:00 RNS ANGLE plc 5.40%
Accelerated bookbuild to raise up to £20m
20Oct20 07:00 RNS-R ANGLE plc 5.40%
Submission accepted by FDA for substantive review
28Sep20 07:00 RNS ANGLE plc 5.40%
Issue of LTIP Options and Share Options
28Sep20 07:00 RNS ANGLE plc 5.40%
ANGLE announces completion of FDA submission
23Sep20 07:00 RNS ANGLE plc 5.40%
Potential treatment strategy to limit metastasis
11Sep20 15:35 RNS Legal & General Group Plc 1.63%
Holding(s) in Company
11Sep20 15:30 RNS ANGLE plc 5.40%
Holding(s) in Company
02Sep20 13:49 RNS ANGLE plc 5.40%
Notification of Interim Results and Webcast
02Sep20 10:00 RNS ANGLE plc 5.40%
Holding(s) in Company
27Aug20 15:13 RNS ANGLE plc 5.40%
Result of 2020 Annual General Meeting
18Aug20 09:30 RNS ANGLE plc 5.40%
Holding(s) in Company
14Aug20 07:00 RNS ANGLE plc 5.40%
Parsortix use to assess response to immunotherapy
06Aug20 12:20 RNS ANGLE plc 5.40%
Holding(s) in Company
05Aug20 07:00 RNS ANGLE plc 5.40%
Notice of AGM and Posting of Annual Report
20Jul20 07:00 RNS ANGLE plc 5.40%
Study: Parsortix use in metastatic breast cancer
08Jul20 17:35 RNS ANGLE plc 5.40%
Holding(s) in Company
08Jul20 17:30 RNS ANGLE plc 5.40%
Holding(s) in Company
08Jul20 17:30 RNS ANGLE plc 5.40%
Holding(s) in Company
25Jun20 07:00 RNS ANGLE plc 5.40%
Preliminary Results
22Jun20 07:00 RNS ANGLE plc 5.40%
Blood donations recommenced for FDA studies
29May20 07:00 RNS ANGLE plc 5.40%
Notice of Results
12May20 07:00 RNS-R ANGLE plc 5.40%
CTC potential as biomarker in MET inhibitor trials
04May20 07:00 RNS-R ANGLE plc 5.40%
Leading cancer centre publishes Parsortix workflow
28Apr20 07:00 RNS ANGLE plc 5.40%
Business Update
17Apr20 07:00 RNS ANGLE plc 5.40%
Parsortix performance in head and neck cancer
31Mar20 07:00 RNS ANGLE plc 5.40%
COVID-19 BUSINESS IMPACT UPDATE
03Mar20 07:00 RNS ANGLE plc 5.40%
Assessing risk of brain metastasis in lung cancer
27Feb20 07:00 RNS-R ANGLE plc 5.40%
Parsortix outperforms other CTC systems in RCC
25Feb20 07:00 RNS-R ANGLE plc 5.40%
ANGLE announce Tri-Con presentation with BioView
17Feb20 07:00 RNS ANGLE plc 5.40%
Data demonstrates key advantages of Parsortix
11Feb20 07:00 RNS-R ANGLE plc 5.40%
Study demonstrates Parsortix potential in melanoma
03Feb20 09:10 RNS ANGLE plc 5.40%
Issue of Equity
30Jan20 07:00 RNS ANGLE plc 5.40%
Interim Results
30Jan20 07:00 RNS ANGLE plc 5.40%
Change of accounting reference date
22Jan20 07:00 RNS ANGLE plc 5.40%
Successful face-to-face meeting with FDA
08Jan20 12:33 RNS ANGLE plc 5.40%
Notice of Results
23Dec19 09:55 RNS ANGLE plc 5.40%
Issue of Equity
07Nov19 07:00 RNS-R ANGLE plc 5.40%
Cancer centre shows Parsortix use in melanoma
30Oct19 14:44 RNS ANGLE plc 5.40%
Result of AGM
30Oct19 07:00 RNS ANGLE plc 5.40%
Q-submission to FDA containing headline data
08Oct19 07:00 RNS ANGLE plc 5.40%
Notice of AGM
04Oct19 17:54 RNS ANGLE plc 5.40%
Holding(s) in Company
04Oct19 07:00 RNS-R ANGLE plc 5.40%
European patent granted for megakaryocyte analysis
Date / Time Company % Chg
01Dec21 07:00 ANGLE plc 5.40%
Angle PLC - Parsortix in RNA analysis of CTCs as tool in NSCLC
26Nov21 17:33 ANGLE plc 5.40%
Angle PLC - Issue of Equity
17Nov21 10:32 ANGLE plc 5.40%
Angle PLC - Issue of Equity
15Nov21 07:00 ANGLE plc 5.40%
Angle PLC - Appointment of Chief Medical Officer
15Nov21 07:00 ANGLE plc 5.40%
Angle PLC - Issue of LTIP Options and Share Options
12Nov21 17:51 ANGLE plc 5.40%
Angle PLC - Issue of Equity
12Nov21 07:00 ANGLE plc 5.40%
Angle PLC - Participation at Jefferies healthcare conference
11Nov21 07:00 ANGLE plc 5.40%
Angle PLC - Parsortix system showcased at NCRI Festival
10Nov21 17:40 ANGLE plc 5.40%
Angle PLC - Issue of Equity
02Nov21 07:00 ANGLE plc 5.40%
Angle PLC - Change of Adviser
21Oct21 17:25 ANGLE plc 5.40%
Angle PLC - Issue of Equity
15Oct21 17:45 ANGLE plc 5.40%
Angle PLC - Issue of Equity
30Sep21 16:02 ANGLE plc 5.40%
Angle PLC - Issue of Equity
30Sep21 07:00 ANGLE plc 5.40%
Angle PLC - Interim Results
27Sep21 07:00 ANGLE plc 5.40%
Angle PLC - Parsortix demonstrates ability to isolate CTCs
22Sep21 07:00 ANGLE plc 5.40%
Angle PLC - Study shows use of Parsortix to assess PD-L1
20Sep21 07:00 ANGLE plc 5.40%
Angle PLC - Parsortix enables gene expression analysis in mPCa
07Sep21 07:00 ANGLE plc 5.40%
Angle PLC - Notice of Interim Results and Webcast
24Aug21 07:00 ANGLE plc 5.40%
Angle PLC - Director/PDMR Shareholding
09Aug21 07:00 ANGLE plc 5.40%
Angle PLC - Study highlights superior performance of Parsortix
06Aug21 13:17 ANGLE plc 5.40%
Angle PLC - Issue of Equity
03Aug21 15:13 ANGLE plc 5.40%
Angle PLC - Issue of Equity
28Jul21 07:00 ANGLE plc 5.40%
Angle PLC - Contract secured for bespoke assay development
09Jul21 07:00 ANGLE plc 5.40%
Angle PLC - Harvesting CTCs from brain metastasis patients
07Jul21 18:34 ANGLE plc 5.40%
Angle PLC - Director/PDMR Shareholding
02Jul21 10:45 ANGLE plc 5.40%
Angle PLC - Issue of Equity
30Jun21 15:44 ANGLE plc 5.40%
Angle PLC - Result of AGM
25Jun21 07:00 ANGLE plc 5.40%
Angle PLC - Result of Accelerated Bookbuild
24Jun21 18:28 ANGLE plc 5.40%
Angle PLC - Accelerated bookbuild to raise up to £20m
18Jun21 11:42 ANGLE plc 5.40%
Angle PLC - Annual General Meeting update
18Jun21 07:00 ANGLE plc 5.40%
Angle PLC - ctDNA and CTCs have differences in EGFR mutations
04Jun21 07:00 ANGLE plc 5.40%
Angle PLC - Update on submission for FDA clearance
01Jun21 07:00 ANGLE plc 5.40%
Angle PLC - Potential to prevent breast cancer relapse
20May21 07:00 ANGLE plc 5.40%
Angle PLC - Parsortix demonstrates oesophageal cancer utility
19May21 16:37 ANGLE plc 5.40%
Angle PLC - Exercise of options and total voting rights
11May21 07:00 ANGLE plc 5.40%
Parsortix study uncovers targets in TNBC patients
30Apr21 11:22 ANGLE plc 5.40%
Exercise of options and total voting rights
29Apr21 07:00 ANGLE plc 5.40%
Preliminary Results
26Apr21 07:00 ANGLE plc 5.40%
Ovarian cancer study patient enrolment completed
16Apr21 07:00 ANGLE plc 5.40%
First large-scale pharma services contract secured
15Apr21 16:10 ANGLE plc 5.40%
Notice of Preliminary Results and Webcast
12Apr21 07:00 ANGLE plc 5.40%
ANGLE's Parsortix system showcased at AACR 2021
30Mar21 07:00 ANGLE plc 5.40%
Global launch of clinical services laboratories
04Mar21 07:00 ANGLE plc 5.40%
Update on submission for FDA clearance
18Feb21 07:00 ANGLE plc 5.40%
Parsortix-harvested CTCs uncover novel biomarker
08Feb21 07:00 ANGLE plc 5.40%
Parsortix: Dynamic assessment of patient response
26Jan21 13:00 ANGLE plc 5.40%
Holding(s) in Company
20Jan21 07:00 ANGLE plc 5.40%
Research confirms high performance of Parsortix
12Jan21 07:00 ANGLE plc 5.40%
Change of Auditor
05Jan21 07:00 ANGLE plc 5.40%
Issue of Equity
09Dec20 07:00 ANGLE plc 5.40%
Parsortix can capture single cancer cell in sample
20Nov20 16:18 AGL LSE,JUP LSE 5.40%
Holding(s) in Company
18Nov20 16:51 ANGLE plc 5.40%
Holding(s) in Company
13Nov20 10:46 ANGLE plc 5.40%
Result of General Meeting
03Nov20 14:54 ANGLE plc 5.40%
Director/PDMR Shareholding
29Oct20 07:00 ANGLE plc 5.40%
Interim Results
27Oct20 18:28 ANGLE plc 5.40%
Result of Placing & Notice of General Meeting
27Oct20 07:00 ANGLE plc 5.40%
Accelerated bookbuild to raise up to £20m
20Oct20 07:00 ANGLE plc 5.40%
Submission accepted by FDA for substantive review
28Sep20 07:00 ANGLE plc 5.40%
Issue of LTIP Options and Share Options
28Sep20 07:00 ANGLE plc 5.40%
ANGLE announces completion of FDA submission
23Sep20 07:00 ANGLE plc 5.40%
Potential treatment strategy to limit metastasis
11Sep20 15:35 AGL LSE,LGEN LSE 1.63%
Holding(s) in Company
11Sep20 15:30 ANGLE plc 5.40%
Holding(s) in Company
02Sep20 13:49 ANGLE plc 5.40%
Notification of Interim Results and Webcast
02Sep20 10:00 AGL LSE,JUP LSE 5.40%
Holding(s) in Company
27Aug20 15:13 ANGLE plc 5.40%
Result of 2020 Annual General Meeting
18Aug20 09:30 AGL LSE,JUP LSE 5.40%
Holding(s) in Company
14Aug20 07:00 ANGLE plc 5.40%
Parsortix use to assess response to immunotherapy
06Aug20 12:20 AGL LSE,JUP LSE 5.40%
Holding(s) in Company
05Aug20 07:00 ANGLE plc 5.40%
Notice of AGM and Posting of Annual Report
20Jul20 07:00 ANGLE plc 5.40%
Study: Parsortix use in metastatic breast cancer
08Jul20 17:35 AGL LSE,JUP LSE 5.40%
Holding(s) in Company
08Jul20 17:30 AGL LSE,JUP LSE 5.40%
Holding(s) in Company
08Jul20 17:30 ANGLE plc 5.40%
Holding(s) in Company
25Jun20 07:00 ANGLE plc 5.40%
Preliminary Results
22Jun20 07:00 ANGLE plc 5.40%
Blood donations recommenced for FDA studies
29May20 07:00 ANGLE plc 5.40%
Notice of Results
12May20 07:00 ANGLE plc 5.40%
CTC potential as biomarker in MET inhibitor trials
04May20 07:00 ANGLE plc 5.40%
Leading cancer centre publishes Parsortix workflow
28Apr20 07:00 ANGLE plc 5.40%
Business Update
17Apr20 07:00 ANGLE plc 5.40%
Parsortix performance in head and neck cancer
31Mar20 07:00 ANGLE plc 5.40%
COVID-19 BUSINESS IMPACT UPDATE
03Mar20 07:00 ANGLE plc 5.40%
Assessing risk of brain metastasis in lung cancer
27Feb20 07:00 ANGLE plc 5.40%
Parsortix outperforms other CTC systems in RCC
25Feb20 07:00 ANGLE plc 5.40%
ANGLE announce Tri-Con presentation with BioView
17Feb20 07:00 ANGLE plc 5.40%
Data demonstrates key advantages of Parsortix
11Feb20 07:00 ANGLE plc 5.40%
Study demonstrates Parsortix potential in melanoma
03Feb20 09:10 ANGLE plc 5.40%
Issue of Equity
30Jan20 07:00 ANGLE plc 5.40%
Interim Results
30Jan20 07:00 ANGLE plc 5.40%
Change of accounting reference date
22Jan20 07:00 ANGLE plc 5.40%
Successful face-to-face meeting with FDA
08Jan20 12:33 ANGLE plc 5.40%
Notice of Results
23Dec19 09:55 ANGLE plc 5.40%
Issue of Equity
07Nov19 07:00 ANGLE plc 5.40%
Cancer centre shows Parsortix use in melanoma
30Oct19 14:44 ANGLE plc 5.40%
Result of AGM
30Oct19 07:00 ANGLE plc 5.40%
Q-submission to FDA containing headline data
08Oct19 07:00 ANGLE plc 5.40%
Notice of AGM
04Oct19 17:54 ANGLE plc 5.40%
Holding(s) in Company
04Oct19 07:00 ANGLE plc 5.40%
European patent granted for megakaryocyte analysis